Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2695 11/11/2024 axicabtagene ciloleucel (Yescarta) Resubmission

Treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

SMC2646 15/01/2024 axicabtagene ciloleucel (Yescarta) Non submission

Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

SMC2189 07/10/2019 axicabtagene ciloleucel (Yescarta) Resubmission

Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.

No medicines have been found.